GB2500549A - Anti-ageing agents - Google Patents

Anti-ageing agents Download PDF

Info

Publication number
GB2500549A
GB2500549A GB1312511.7A GB201312511A GB2500549A GB 2500549 A GB2500549 A GB 2500549A GB 201312511 A GB201312511 A GB 201312511A GB 2500549 A GB2500549 A GB 2500549A
Authority
GB
United Kingdom
Prior art keywords
ageing
materials
combination
relates
identifying
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB1312511.7A
Other versions
GB201312511D0 (en
Inventor
Abigail Kate Langton
Christopher Ernest Maitland Griffiths
Michael John Sherratt
Rachel Elizabeth Beatrice Watson
Neil Kerslake Gibbs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Manchester
Original Assignee
University of Manchester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Manchester filed Critical University of Manchester
Publication of GB201312511D0 publication Critical patent/GB201312511D0/en
Publication of GB2500549A publication Critical patent/GB2500549A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6881—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from skin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/906—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7)
    • G01N2333/90605—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on the CH-NH2 group of donors (1.4)
    • G01N2333/90633—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3) in general
    • G01N2333/90638—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3) in general with a definite EC number (1.4.3.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7042—Aging, e.g. cellular aging

Abstract

This invention relates to a method for identifying an anti-ageing agent for use in skincare compositions, by determining the ability of a material or a combination of materials to modulate the expression of molecules associated with microfibril or elastic fibres. More specifically, the invention relates to a method for identifying an anti-ageing agent by determining the ability of a material or combination of materials to downregulate LOXL-1 expression. The invention also relates to methods for assessing the anti-ageing effect of a material or combination of materials on the skin, anti-ageing agents identified by such methods, and compositions containing them.
GB1312511.7A 2010-12-17 2011-12-16 Anti-ageing agents Withdrawn GB2500549A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201021457A GB201021457D0 (en) 2010-12-17 2010-12-17 Anti-ageing agents
PCT/GB2011/052498 WO2012080747A2 (en) 2010-12-17 2011-12-16 Anti-ageing agents

Publications (2)

Publication Number Publication Date
GB201312511D0 GB201312511D0 (en) 2013-08-28
GB2500549A true GB2500549A (en) 2013-09-25

Family

ID=43598573

Family Applications (2)

Application Number Title Priority Date Filing Date
GB201021457A Ceased GB201021457D0 (en) 2010-12-17 2010-12-17 Anti-ageing agents
GB1312511.7A Withdrawn GB2500549A (en) 2010-12-17 2011-12-16 Anti-ageing agents

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GB201021457A Ceased GB201021457D0 (en) 2010-12-17 2010-12-17 Anti-ageing agents

Country Status (2)

Country Link
GB (2) GB201021457D0 (en)
WO (1) WO2012080747A2 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2402676A (en) * 2003-06-13 2004-12-15 Coletica Use of the lysyl oxidase-like (LOXL) enzyme to stimulate formation of elastic fibres
WO2005069975A2 (en) * 2004-01-23 2005-08-04 Massachusetts Eye & Ear Infirmary Lysyl oxidase-like 1 (loxl1) and elastogenesis
US20060134172A1 (en) * 2004-12-21 2006-06-22 Alcon, Inc. Agents which regulate, inhibit, or modulate the activity and/or expression of lysyl oxidase (LOX) and LOX-like proteases as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
WO2008152656A2 (en) * 2007-06-13 2008-12-18 Decode Genetics Ehf Genetic variants on chr 15q24 as markers for use in diagnosis, prognosis and treatment of exfoliation syndrome and glaucoma
WO2009079126A1 (en) * 2007-12-19 2009-06-25 Avon Products, Inc. Topical compositions comprising non-proteogenic amino acids and methods of treating skin
WO2009085443A1 (en) * 2007-12-21 2009-07-09 Avon Products, Inc. Topical compositions containing desthiobiotin and its derivatives and a method of treating skin

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2402676A (en) * 2003-06-13 2004-12-15 Coletica Use of the lysyl oxidase-like (LOXL) enzyme to stimulate formation of elastic fibres
WO2005069975A2 (en) * 2004-01-23 2005-08-04 Massachusetts Eye & Ear Infirmary Lysyl oxidase-like 1 (loxl1) and elastogenesis
US20060134172A1 (en) * 2004-12-21 2006-06-22 Alcon, Inc. Agents which regulate, inhibit, or modulate the activity and/or expression of lysyl oxidase (LOX) and LOX-like proteases as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
WO2008152656A2 (en) * 2007-06-13 2008-12-18 Decode Genetics Ehf Genetic variants on chr 15q24 as markers for use in diagnosis, prognosis and treatment of exfoliation syndrome and glaucoma
WO2009079126A1 (en) * 2007-12-19 2009-06-25 Avon Products, Inc. Topical compositions comprising non-proteogenic amino acids and methods of treating skin
WO2009085443A1 (en) * 2007-12-21 2009-07-09 Avon Products, Inc. Topical compositions containing desthiobiotin and its derivatives and a method of treating skin

Also Published As

Publication number Publication date
GB201021457D0 (en) 2011-02-02
WO2012080747A3 (en) 2013-08-22
WO2012080747A2 (en) 2012-06-21
GB201312511D0 (en) 2013-08-28

Similar Documents

Publication Publication Date Title
MX2013014544A (en) Gene therapy vectors for adrenoleukodystrophy and adrenomyeloneuropathy.
CL2015002066A1 (en) Compositions that include agents for conferring hydrophobic character and stabilizers and methods for making and using them.
BR112012019693A2 (en) antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use for them.
MX369740B (en) Antibodies against claudin 18.2 useful in cancer diagnosis.
BR112014026740A2 (en) antibody, composition, methods for treating a mammal and for providing an enhanced adcc antibody, and use of an antibody
FR2964565B1 (en) COSMETIC COMPOSITION COMPRISING A FIXING POLYMER AND ANTIPELLICULAR AGENT
JO3118B1 (en) Compositions and methods for antibodies targeting complement protein c5
MX350773B (en) Methods and compositions for weed control.
EP3995142A3 (en) Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
BR112014002769A2 (en) depilatory method and kit
MX2014014898A (en) Systems and methods for identifying cosmetic agents for hair/scalp care compositions.
MX365321B (en) Methods for treating neutropenia using retinoid agonists.
MX355401B (en) Elastic fiber containing an anti-tack additive.
MX2018015349A (en) In vivo synthesis of elastic fiber.
MX366410B (en) Compositions and methods for treating and repairing tendons.
TR201909824T4 (en) Bushing mechanisms and related methods.
BR112012021411A2 (en) braf mutations that confer resistance to braf inhibitors.
EP3622069A4 (en) Compositions and methods for loading extracellular vesicles with chemical and biological agents/molecules
MX337504B (en) Methods of making and using elastic fiber containing an anti-tack additive.
BR112014001066A2 (en) botulinum toxins for use in a method for treating adipose deposits
BRPI0912532A2 (en) method and device for treating a surface of a fiber composite material
BR112013021035A2 (en) improved soft tissue replacement compositions and methods
NZ710949A (en) Modified glycolipids and methods of making and using the same
GB201312511D0 (en) Anti-ageing agents
GB2494570A (en) Anti-ageing agents

Legal Events

Date Code Title Description
732E Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)

Free format text: REGISTERED BETWEEN 20150730 AND 20150805

WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)